New cell therapy targets Tough-to-Treat lymphoma
NCT ID NCT07369492
Summary
This early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy for adults with B-cell lymphoma that has returned or hasn't responded to other treatments. The therapy involves modifying a patient's own immune cells to target a protein called BAFF-R on their cancer cells. Researchers will enroll about 30 participants to see how well the treatment is tolerated and if it helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Suzhou Hongci Hematology Hospital
RECRUITINGSuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.